Mariana Krutman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mariana Krutman has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Nelson Wolosker
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
19 shared publications - Pedro Puech-Leão
Department of Vascular Surgery, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
11 shared publications Kenji Nishinari
Division of Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil
7 shared publications- Marcelo Passos Teivelis
Hospital Israelita Albert Einstein, Brazil; Faculdade Israelita de Ciências da Saúde Albert Einstein, Brazil
7 shared publications Paulo Kauffman
Department of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil
7 shared publicationsBruno Soriano Pignataro
Division of Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil
4 shared publications
Latest Publications
- 23 May 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 121, 167-172
Survival and Patency Outcomes in a 10-year Experience of Cephalic Pancreatectomy Associated with Portomesenteric Venous Reconstruction
- 23 May 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 121, 167-172
Survival and Patency Outcomes in a 10-year Experience of Cephalic Pancreatectomy Associated with Portomesenteric Venous Reconstruction
- 21 April 2022
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 86, 219-228
Postoperative Anticoagulation in Vascular Reconstructions Associated with Malignancies
- 21 April 2022
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 86, 219-228
Postoperative Anticoagulation in Vascular Reconstructions Associated with Malignancies
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 20
Is routine screening for silent pulmonary embolism justified in patients with deep vein thrombosis?
The incidence of asymptomatic pulmonary embolism (PE) exceeds 70% in patients with deep venous thrombosis (DVT), even in cases of distal deep vein thrombosis. We report the case of a patient with a diagnosis of DVT in the lower left limb associated with asymptomatic PE who presented late symptoms due to this same PE. The absence of acute symptoms and the late onset of symptoms could have provoked doubts about the most appropriate treatment, resulting in unnecessary interventions, if pulmonary embolism had not already been diagnosed with tomography. In the present case, we demonstrate that computed tomography angiography conducted at the time of DVT diagnosis accurately diagnosed PE and prevented any misinterpretation of recurrent DVT in a patient already being medicated, which could have been mistakenly interpreted as demonstrating failure of anticoagulant therapy. Such a situation could lead to unnecessary intervention to fit an inferior vena cava filter. We cannot suggest that a classic medical conduct should be reformulated simply on the basis of a case report. However, we would be remiss not to suggest that well-designed studies should be carried out in the future to assess the need for this examination in the acute phase.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 20
Open AccessIs routine screening for silent pulmonary embolism justified in patients with deep vein thrombosis?
The incidence of asymptomatic pulmonary embolism (PE) exceeds 70% in patients with deep venous thrombosis (DVT), even in cases of distal deep vein thrombosis. We report the case of a patient with a diagnosis of DVT in the lower left limb associated with asymptomatic PE who presented late symptoms due to this same PE. The absence of acute symptoms and the late onset of symptoms could have provoked doubts about the most appropriate treatment, resulting in unnecessary interventions, if pulmonary embolism had not already been diagnosed with tomography. In the present case, we demonstrate that computed tomography angiography conducted at the time of DVT diagnosis accurately diagnosed PE and prevented any misinterpretation of recurrent DVT in a patient already being medicated, which could have been mistakenly interpreted as demonstrating failure of anticoagulant therapy. Such a situation could lead to unnecessary intervention to fit an inferior vena cava filter. We cannot suggest that a classic medical conduct should be reformulated simply on the basis of a case report. However, we would be remiss not to suggest that well-designed studies should be carried out in the future to assess the need for this examination in the acute phase.
- Open Access
Trends in abdominal aortic aneurysm-related mortality in Brazil, 2000-2016: a multiple-cause-of-death study
Remarkable changes in the epidemiology of abdominal aortic aneurysm (AAA) have occurred in many countries during last few decades, which have also affected Brazilian mortality concurrently. This study aimed to investigate mortality trends related to AAA ...
Open AccessTrends in abdominal aortic aneurysm-related mortality in Brazil, 2000-2016: a multiple-cause-of-death study
Remarkable changes in the epidemiology of abdominal aortic aneurysm (AAA) have occurred in many countries during last few decades, which have also affected Brazilian mortality concurrently. This study aimed to investigate mortality trends related to AAA ...
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 19
An alternative approach to treatment of inferior vena cava filter perforation
We report a case of inferior vena cava filter perforation immediately after filter implantation, recognized intraoperatively in a patient undergoing laparotomy for resection of locally advanced ovarian cancer. We describe an alternative approach with strut resection, less invasive than filter removal, enabling the device to be maintained and bleeding to be controlled.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 19
Open AccessAn alternative approach to treatment of inferior vena cava filter perforation
We report a case of inferior vena cava filter perforation immediately after filter implantation, recognized intraoperatively in a patient undergoing laparotomy for resection of locally advanced ovarian cancer. We describe an alternative approach with strut resection, less invasive than filter removal, enabling the device to be maintained and bleeding to be controlled.
- 1 June 2019
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 69 (6) , 1880-1888
Twenty years of experience in vascular reconstructions associated with resection of malignant neoplasms in a single cancer center
- 1 June 2019
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 69 (6) , 1880-1888
Twenty years of experience in vascular reconstructions associated with resection of malignant neoplasms in a single cancer center
- Open Access
- 27 December 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 23 (7) , 883-887
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience
Purpose: To study the safety and efficacy of rivaroxaban—a direct oral anticoagulant—use in patients with active cancer and venous thromboembolism (VTE). Patients and Methods: Retrospective cohort study of 400 patients with active cancer and associated VTE, defined as deep venous thrombosis and/or pulmonary embolism. This single-center study was carried out from January 2012 to June 2015. The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban. Results: Of the 400 patients enrolled, 223 (55.8%) were female. A total of 362 (90.5%) patients had solid tumors and 244 (61%) had metastatic disease. A total of 302 (75.5%) received initial parenteral therapy with enoxaparin (median: 3, mean: 5.6, standard deviation [SD]: 6.4 days) followed by rivaroxaban. Ninety-eight patients (24.5%) were treated with on label rivaroxaban treatment. Recurrence rates were 3.25% with major bleeding occurring in 5.5% during the anticoagulant therapy (median: 118, mean: 163.9, SD: 159.9 days). Conclusion: Rivaroxaban can be an attractive alternative for the treatment of cancer-associated thrombosis.
- 27 December 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 23 (7) , 883-887
Open AccessOral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience
Purpose: To study the safety and efficacy of rivaroxaban—a direct oral anticoagulant—use in patients with active cancer and venous thromboembolism (VTE). Patients and Methods: Retrospective cohort study of 400 patients with active cancer and associated VTE, defined as deep venous thrombosis and/or pulmonary embolism. This single-center study was carried out from January 2012 to June 2015. The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban. Results: Of the 400 patients enrolled, 223 (55.8%) were female. A total of 362 (90.5%) patients had solid tumors and 244 (61%) had metastatic disease. A total of 302 (75.5%) received initial parenteral therapy with enoxaparin (median: 3, mean: 5.6, standard deviation [SD]: 6.4 days) followed by rivaroxaban. Ninety-eight patients (24.5%) were treated with on label rivaroxaban treatment. Recurrence rates were 3.25% with major bleeding occurring in 5.5% during the anticoagulant therapy (median: 118, mean: 163.9, SD: 159.9 days). Conclusion: Rivaroxaban can be an attractive alternative for the treatment of cancer-associated thrombosis.
- Open Access
- 5 January 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 22 (4) , 377-380
Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism
Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE). On its major clinical trials, treatment was initiated directly with a 3-week dose of oral 15 mg twice daily followed by 20 mg every day for at least 3 months. We retrospectively evaluated an initial therapy for confirmed VTE with 1 to 18 days of enoxaparin (1 mg/kg twice daily parenteral) followed by oral rivaroxaban 20 mg every day. Of 49 patients, we found no symptomatic recurrence, no major bleeding, and only 1 clinically relevant nonmajor bleeding. We concluded in this pilot study that it is safe and effective to treat patients with enoxaparin course followed directly by a dose of 20 mg of rivaroxaban.
- 5 January 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 22 (4) , 377-380
Open AccessEnoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism
Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE). On its major clinical trials, treatment was initiated directly with a 3-week dose of oral 15 mg twice daily followed by 20 mg every day for at least 3 months. We retrospectively evaluated an initial therapy for confirmed VTE with 1 to 18 days of enoxaparin (1 mg/kg twice daily parenteral) followed by oral rivaroxaban 20 mg every day. Of 49 patients, we found no symptomatic recurrence, no major bleeding, and only 1 clinically relevant nonmajor bleeding. We concluded in this pilot study that it is safe and effective to treat patients with enoxaparin course followed directly by a dose of 20 mg of rivaroxaban.
- Open Access
- 18 November 2014
- Published by FapUNIFESP (SciELO) in Einstein (São Paulo)
- Vol. 12 (4) , 499-501
Uso combinado de endoprótese GORE TAG® e Gore Exculder® para tratamento de aneurisma de aorta abdominal com angulação extrema
O avanço tecnológico da cirurgia endovascular no tratamento de aneurismas de aorta vem permitindo que uma maior quantidade de pacientes, antes considerados inaptos para essa abordagem, beneficie-se dessa modalidade terapêutica. Apesar da atual disponibilidade de endopróteses com alta conformabilidade, casos com anatomia desfavorável permanecem um desafio para os cirurgiões. Descrevemos um caso anatomicamente desfavorável, resolvido com sucesso pela técnica endovascular, utilizando-se uma manobra não convencional.
- 18 November 2014
- Published by FapUNIFESP (SciELO) in Einstein (São Paulo)
- Vol. 12 (4) , 499-501
Open AccessUso combinado de endoprótese GORE TAG® e Gore Exculder® para tratamento de aneurisma de aorta abdominal com angulação extrema
O avanço tecnológico da cirurgia endovascular no tratamento de aneurismas de aorta vem permitindo que uma maior quantidade de pacientes, antes considerados inaptos para essa abordagem, beneficie-se dessa modalidade terapêutica. Apesar da atual disponibilidade de endopróteses com alta conformabilidade, casos com anatomia desfavorável permanecem um desafio para os cirurgiões. Descrevemos um caso anatomicamente desfavorável, resolvido com sucesso pela técnica endovascular, utilizando-se uma manobra não convencional.
- 1 November 2014
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 28 (8) , 1878-1884
Late Surgical Outcomes of Carotid Resection and Saphenous Vein Graft Revascularization in Patients with Advanced Head and Neck Squamous Cell Carcinoma
- 1 November 2014
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 28 (8) , 1878-1884
Late Surgical Outcomes of Carotid Resection and Saphenous Vein Graft Revascularization in Patients with Advanced Head and Neck Squamous Cell Carcinoma